Recent Advances in Antidotes for Direct Oral Anticoagulants: Their Arrival Is Imminent

The results of early trials evaluating the tolerability, efficacy,and safety of specific antidotes for the DOACs are promising (Table 2), but none of these agents are as yet approved for clinical use. Until they are approved, clinicians attempting to reverse the anticoagulant effects of DOACs will be limited to the use of general hemostatic agents, such as(activated) PCCs or rFVIIa,3-12 and to hemodialysis or hemofiltration for removal of DOACs …